Metrizamide

Source: Wikipedia, the free encyclopedia.
Metrizamide
Clinical data
Trade namesAmipaque
Other names3-aAcetamido-2,4,6-triiodo-5-(N-methylacetamido)-N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Identifiers
  • 2-({3-(Acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoyl}amino)-2-deoxy-D-glucopyranose
ECHA InfoCard
100.045.872 Edit this at Wikidata
Chemical and physical data
FormulaC18H22I3N3O8
Molar mass789.100 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Metrizamide is a

non-ionic iodine-based radiocontrast agent.[1] It is also a density gradient medium for the centrifugation of biological particles.[2]

Historically metrizamide replaced

X-ray study of the spine now largely replaced by MRI
). The radio opacity characteristics are such that finer detail is displayed with metrizamide, as well as the advantage of reabsorption from spinal fluid and excretion from the body – since unlike iofendylate, metrizamide is a water-soluble substance.

Both agents are administered by

blood brain barrier
, side effects are more likely encountered. Issues related to absorption into the general circulation are also encountered.

Side effects

History

Metrizamide was approved in the US in 1978. Its marketing is discontinued as of 2021.[5]

References

  1. PMID 6103672
    .
  2. ^ Inaba, Kayo (2011). Current Protocols in Immunology. Isolation of Dendritic Cells: Wiley. p. 3.7.14.
  3. ^ Kassicieh et al. (1988), Conduction aphasia following metrizamide myelography, J Am Osteopath Assoc 1988 Vol. 88 Issue 3 Pages 384-6
  4. PMID 6824454
    .
  5. ^ "Drugs@FDA: FDA-Approved Drugs: Amipaque". Food and Drug Administration. Retrieved 2021-03-31.

Further reading

External links